Northwest vs Feuerstein rhubarb round 4

|About: Northwest Biotherapeut... (NWBO)|By:, SA News Editor

Northwest Biotherapeutics (NWBO -0.2%) takes umbrage with TheStreet's Adam Feuerstein in response to his May 27 article asserting that the company's DCVax isn't working. He says the company's stated maximum tumor shrinkage of 28% in some Phase 1 trial patients falls short of the globally-accepted RECIST standard of at least a 30% reduction to qualify as a valid partial response.

The rhubarb began in March.